Viking Therapeutics Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 46-1073877(I.R.S. EmployerIdentification Number) Delaware(State or other jurisdiction ofincorporation or organization) 92121(Zip Code) (858)704-4660(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: ClassNumber of Shares Outstandingas of April 15, 2025Common stock, $0.00001 par value112,309,545 VIKING THERAPEUTICS, INC.FORM 10-Q FOR THE THREE MONTHS ENDED MARCH 31, 2025TABLE OF CONTENTS PagePart I.FINANCIAL INFORMATION1Item 1.Consolidated Financial Statements1Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 20241Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025and 2024 (unaudited)2Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024(unaudited)3Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (unaudited)4Notes to Consolidated Financial Statements (unaudited)5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures26Part II.OTHER INFORMATION28Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds65Item 3.Defaults Upon Senior Securities65Item 4.Mine Safety Disclosures65Item 5.Other Information66Item 6.Exhibits67SIGNATURES68 Viking Therapeutics, Inc.Consolidated BalanceSheets (In thousands, except share and per share amounts) Viking Therapeutics, Inc.Consolidated Statements of Operationsand Comprehensive Loss (In thousands, except per share amounts)(Unaudited) Viking Therapeutics, Inc.Consolidated Statements of Stockholders’ Equity (In thousands, except share amounts)(Unaudited) Viking Therapeutics, Inc.Consolidated Statements of Cash Flows (In thousands)(Unaudited) Viking Therapeutics, Inc.NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Organization and Summary of Significant Accounting Policies The Company Viking Therapeutics, Inc., a Delaware corporation, together with its subsidiaries (the “Company”), is a clinical-stagebiopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. In June 2021,the Company formed an Australian subsidiary, Viking Therapeutics, PTY LTD, so as to be able to take advantage of certainresearch and development reimbursements available to local Australian-based research and development companies that choose todo research in Australia. In January 2025, the Company formed an Irish subsidiary, Viking Therapeutics Ireland Limited. The Company was incorporated under the laws of the State ofDelawareonSeptember 24, 2012and its principal executive officesare located in San Diego, California, with a subsidiary located in Adelaide, Australia and a subsidiary located in Dublin, Ireland. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principlesgenerally ac